Join us for a unique opportunity to hear the story behind one of the most remarkable examples of AI and precision medicine in cancer care.

Jacob Stern leads operations and investments for the personalized medical team surrounding Sid Sijbrandij. Jacob is pioneering a data-driven, N=1 approach to treating Sid’s high-grade osteosarcoma, overseeing a portfolio of experimental therapeutics and novel diagnostic assays.

Jacob previously led the spatial transcriptomics product line at 10x Genomics. Prior to his work in life sciences, he focused on data integration at Palantir Technologies and strategy at BCG. He holds an MBA and BA from Stanford University.

Through Sid’s journey, and from the people directly involved, we’ll explore how AI, genomic insights, and clinical expertise came together to identify a personalized treatment strategy. We’ll also discuss the evolving role of the physician in an era where AI is becoming an integral part of clinical decision-making.

We look forward to an engaging discussion on what this story can teach us about the future of precision oncology.